Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States

Novartis Pharmaceuticals287 enrolled

Overview

This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutation who received treatment with capmatinib, immunotherapy (IO), or chemotherapy (CT) in real-world practice settings. Data abstraction was performed by the participating physician.

Study Type

OBSERVATIONAL

Enrollment

287

Conditions

Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient was aged ≥ 18 years at the time of NSCLC diagnosis. * Had histologically confirmed advanced (stage IIIB, IIIC, or IV) NSCLC with MET exon 14 skipping mutation. * Initiated first-line (1L) treatment for aNSCLC between 1 January 2017 and date of data abstraction with one of the following treatment regimen: * Capmatinib * IO agent in monotherapy (e.g., atezolizumab, pembrolizumab) * CT regimen, single agent or combinations of CT agents (e.g., platinum agents, taxane agents, gemcitabine, pemetrexed) * Combination regimen containing IO and CT agents * Had ≥ 6 months of potential follow-up time after the initiation of 1L treatment for aNSCLC, except if the patient died sooner. * Living or deceased at the time of chart abstraction. Exclusion Criteria: * Presence of other mutations (e.g., EGFR, ALK, ROS1, RET, NTRK, BRAF, or KRAS) at any time. * Treatment with other MET inhibitors such as crizotinib or tepotinib at any time during the study period. * Participation in clinical trials related to treatment for NSCLC at any timepoint.

Locations (1)

Novartis

East Hanover, New Jersey, United States